These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 31872760)

  • 21. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
    Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
    Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
    Loc WS; Linton SS; Wilczynski ZR; Matters GL; McGovern CO; Abraham T; Fox T; Gigliotti CM; Tang X; Tabakovic A; Martin JA; Clawson GA; Smith JP; Butler PJ; Kester M; Adair JH
    Nanomedicine; 2017 Oct; 13(7):2313-2324. PubMed ID: 28673852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
    Han H; Hou Y; Chen X; Zhang P; Kang M; Jin Q; Ji J; Gao M
    J Am Chem Soc; 2020 Mar; 142(10):4944-4954. PubMed ID: 32069041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plectin-1-targeted recognition for enhancing comprehensive therapy in pancreatic ductal adenocarcinoma.
    Zhu Q; Zeng S; Yang J; Zhuo J; Wang P; Wen S; Fang C
    Nanoscale; 2024 Oct; 16(39):18584-18596. PubMed ID: 39291372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
    Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
    Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer.
    Bulanadi JC; Xue A; Gong X; Bean PA; Julovi SM; de Campo L; Smith RC; Moghaddam MJ
    Chempluschem; 2020 Jun; 85(6):1283-1291. PubMed ID: 32543086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
    Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
    Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
    J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
    Courtin A; Richards FM; Bapiro TE; Bramhall JL; Neesse A; Cook N; Krippendorff BF; Tuveson DA; Jodrell DI
    PLoS One; 2013; 8(6):e67330. PubMed ID: 23840665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Palam LR; Gore J; Craven KE; Wilson JL; Korc M
    Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
    Dunlop CR; Wallez Y; Johnson TI; Bernaldo de Quirós Fernández S; Durant ST; Cadogan EB; Lau A; Richards FM; Jodrell DI
    Br J Cancer; 2020 Oct; 123(9):1424-1436. PubMed ID: 32741974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
    She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
    J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.
    Soni KS; Thomas D; Caffrey T; Mehla K; Lei F; O'Connell KA; Sagar S; Lele SM; Hollingsworth MA; Radhakrishnan P; Bronich TK
    J Pharmacol Exp Ther; 2019 Sep; 370(3):894-901. PubMed ID: 30683666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
    Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.